Skip to main content

Client News

Abivax Publishes in Nature Scientific Reports ABX464’s Unique Mechanism of Action Leading to Both Anti-Inflammatory and Antiviral Effects

28th January 2019
www.abivax.com

HPS Home Power Solutions GmbH announces first closing of its financing round at € 7.5 million

24th January 2019
www.homepowersolutions.de

Ergomed plc: Board and Management Changes

23rd January 2019
www.ergomedplc.com

Abivax Hosts KOL Event in Geneva on Therapeutic Candidate ABX464 for Ulcerative Colitis

23rd January 2019
www.abivax.com

nova funds: Gesundheitsaktienfonds nova Steady HealthCare erzielt 2018 erneut sehr gutes Ergebnis

17th January 2019
www.novafunds.biz

Medigene AG: Medigene participates at four upcoming conferences

17th January 2019
www.medigene.com

Allergy Therapeutics announces business development ppdate and publication date of half year results for FY 2018/2019

16th January 2019
www.allergytherapeutics.com

Newron Pharmaceuticals: Commercialization partner Zambon together with Valeo Pharma announce the approval of Onstryv® (safinamide) for Parkinson’s disease in Canada

16th January 2019
www.newron.com

Adocia confirms its financial calendar for 2019

16th January 2019
www.adocia.com

Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance

14th January 2019
www.veronapharma.com
Load more